Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, ≥97%(HPLC) Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 24 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Gambogic acid causes an irreversible arrest in the G2/M phase of the cell cycle. It acts as a caspase activator and apoptosis inducer
| Pubchem Sid | 504764974 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504764974 |
| Sonrisas canónicas | CC(=CCCC1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)OC45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)C)C |
| IUPAC Name | (Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid |
| InChIKey | GEZHEQNLKAOMCA-RRZNCOCZSA-N |
| INCHI | 1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16,18,23,27,39H,9,12,15,17,19H2,1-8H3,(H,42,43)/b22-13-/t23-,27+,36-,37+,38-/m1/s1 |
| Isómeros SMILES | CC(=CCC[C@@]1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)O[C@@]45[C@H]6C[C@@H](C=C4C3=O)C(=O)[C@@]5(OC6(C)C)C/C=C(/C)\C(=O)O)O)C)C |
| WGK Alemania | 1 |
| RTECS | PB9268200 |
| Número ONU | 1356 |
| Peso molecular | 628.75 |
| Reaxy-Rn | 1339863 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=1339863&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Clase | Benzopyrans |
| Subclass | 1-benzopyrans |
| Intermediate Tree Nodes | Dibenzopyrans - Xanthenes - Xanthones |
| Direct Parent | Pyranoxanthones |
| Alternative Parents | Pyranochromenes Chromones Aromatic monoterpenoids Aryl ketones Oxepanes Alkyl aryl ethers Cyclohexenones Benzenoids Vinylogous acids Tetrahydrofurans Oxacyclic compounds Monocarboxylic acids and derivatives Dialkyl ethers Carboxylic acids Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Pyranoxanthone - Pyranochromene - Chromone - Aromatic monoterpenoid - Monoterpenoid - Aryl ketone - Alkyl aryl ether - Cyclohexenone - Oxepane - Benzenoid - Vinylogous acid - Tetrahydrofuran - Ketone - Monocarboxylic acid or derivatives - Oxacycle - Ether - Dialkyl ether - Carboxylic acid - Carboxylic acid derivative - Hydrocarbon derivative - Organic oxide - Carbonyl group - Organic oxygen compound - Organooxygen compound - Aromatic heteropolycyclic compound |
| Descripción | This compound belongs to the class of organic compounds known as pyranoxanthones. These are organic aromatic compounds containing a pyran or a hydrogenated derivative fused to a xanthone ring system. |
| External Descriptors | pyranoxanthones |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
| Certificate of Analysis | Sep 12, 2025 | G101480 | |
| Certificate of Analysis | Sep 12, 2025 | G101480 | |
| Certificate of Analysis | Aug 11, 2025 | G101480 | |
| Certificate of Analysis | Aug 11, 2025 | G101480 | |
| Certificate of Analysis | Jul 25, 2025 | G101480 | |
| Certificate of Analysis | Jul 25, 2025 | G101480 | |
| Certificate of Analysis | Feb 08, 2025 | G101480 | |
| Certificate of Analysis | Feb 08, 2025 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Jul 10, 2024 | G101480 | |
| Certificate of Analysis | Dec 21, 2023 | G101480 | |
| Certificate of Analysis | Dec 21, 2023 | G101480 | |
| Certificate of Analysis | Dec 21, 2023 | G101480 | |
| Certificate of Analysis | Nov 01, 2021 | G101480 |
| Solubilidad | DMSO: ≥100 mg/mL;H2O: insoluble;Ethanol:100 mg/mL |
|---|---|
| Punto de ebullición (°C) | 280°C |
| Punto de fusión (°C) | 81.8°C |
| Peso molecular | 628.700 g/mol |
| XLogP3 | 7.300 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Exact Mass | 628.304 Da |
| Monoisotopic Mass | 628.304 Da |
| Topological Polar Surface Area | 119.000 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 1490.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 1 |
| Covalently-Bonded Unit Count | 1 |
| 1. Dinghu Zhang, Yanhong Chu, Hanqing Qian, Lingyu Qian, Jie Shao, Qiuping Xu, Lixia Yu, Rutian Li, Quanan Zhang, Fenglei Wu, Baorui Liu, Qin Liu. (2023) Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer. International Journal of Nanomedicine, [PMID:32099362] [10.2147/IJN.S231448] |
| 2. Lili Qian, Qian Li, Zhenshan Ding, Kejun Luo, Jiamin Su, Jiawei Chen, Guangying Zhu, Zhihua Gan, Qingsong Yu. (2022) Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor. ACS Applied Materials & Interfaces, [PMID:36525559] [10.1021/acsami.2c14628] |
| 3. Yuhan Wang, Chunyan Yue, Mengyao Zhang, Dazhao Li, Tao Xu, Mengying He, Mengyuan Wang, Yanan Zhao, Zihui Ni, Feng Zhi, Yiqiao Hu, Dawei Ding. (2022) Dually enhanced phototherapy by gambogic acid and hyperthemia-activated chemotherapy for synergistic breast cancer treatment. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2022.139108] |
| 4. Shu-Ting Xu, Cheng Yang, Xiu-Ping Yan. (2021) Nanothorn Filter-Facilitated Online Cell Lysis for Rapid and Deep Intracellular Profiling by Single-Cell Mass Spectrometry. ANALYTICAL CHEMISTRY, [PMID:34784185] [10.1021/acs.analchem.1c03529] |
| 5. Lulu Cai, Lina Dong, Xuan Sha, Shuai Zhang, Siwen Liu, Xiaoxi Song, Mingming Zhao, Qi Wang, Kai Xu, Jingjing Li. (2021) Exfoliation and in situ functionalization of MoS2 nanosheets for MRI-guided combined low-temperature photothermal therapy and chemotherapy. MATERIALS & DESIGN, [PMID:] [10.1016/j.matdes.2021.110020] |
| 6. Zhang Gutian, Cheng Wenting, Du Lin, Xu Chuanjun, Li Jinlong. (2021) Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-13). [PMID:33407570] [10.1186/s12951-020-00749-5] |
| 7. Chen Jun, Li Lihua, Zhou Yun, Zhang Jiahua, Chen Lei. (2020) Gambogic acid ameliorates high glucose– and palmitic acid–induced inflammatory response in ARPE-19 cells via activating Nrf2 signaling pathway: ex vivo. CELL STRESS & CHAPERONES, 26 (2): (367-375). [PMID:33245515] [10.1007/s12192-020-01182-1] |
| 8. Jinghua Li, Daoming Zhu, Weijie Ma, Yang Yang, Ganggang Wang, Xiaoling Wu, Kunlei Wang, Yiran Chen, Fubing Wang, Wei Liu, Yufeng Yuan. (2020) Rapid synthesis of a Bi@ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma. Nanoscale, 12 (32): (17064-17073). [PMID:32785323] [10.1039/D0NR03907A] |
| 9. Dinghu Zhang, Zhengyun Zou, Wei Ren, Hanqing Qian, Qianfeng Cheng, Liulian Ji, Baorui Liu, Qin Liu. (2018) Gambogic acid-loaded PEG–PCL nanoparticles act as an effective antitumor agent against gastric cancer. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, [PMID:29069711] [10.1080/10837450.2017.1295068] |
| 10. Ouyang Boshu, Shan Caihua, Shen Shun, Dai Xinnan, Chen Qingwang, Su Xiaomin, Cao Yongbin, Qin Xifeng, He Ying, Wang Siyu, Xu Ruizhe, Hu Ruining, Shi Leming, Lu Tun, Yang Wuli, Peng Shaojun, Zhang Jun, Wang Jianxin, Li Dongsheng, Pang Zhiqing. (2024) AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer. Nature Communications, 15 (1): (1-20). [PMID:39215014] [10.1038/s41467-024-51980-9] |
| 11. Huapan Fang, Lin Zhang, Yicheng Wu, Linfu Chen, Zheng Deng, Zixuan Zheng, Yudong Wang, Yang Yang, Qian Chen. (2024) Carrier-free multifunctional nanomedicine for enhanced hyperthermic intraperitoneal chemotherapy against abdominal pelvic tumors. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2024.155781] |
| 12. Zhongkai Chen, Qinghua Zhan, Yifan Yan, Yanfei Cai, Zhaoqi Yang. (2024) Covalent Organic Framework Based Nanocomposite for Low Temperature Photothermal Therapy. ChemistrySelect, 9 (28): (e202401909). [PMID:] [10.1002/slct.202401909] |
| 13. Yang Mei, Huang Yida, Chen Zhongxing, Ye Qianfang, Zeng Zhenhai, You Xinru, Bao Bijun, Xing Wenqian, Zhao Nan, Zou Zhilin, Pan Hongxian, Chen Xin, Gao Qingyi, Chen Tingting, Zhang Shenrong, Chen Aodong, Xiao Yichen, Xu Huilin, Li Jiawei, Li Yongjiang, Kong Na, Tao Wei, Zhou Xingtao, Huang Jinhai. (2025) Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy. Nature Communications, 16 (1): (1-21). [PMID:40634298] [10.1038/s41467-025-60454-5] |
| 14. Xin Zhang, Li Li, Haiqing Niu, Zixin Liang, Liuqi Sang, Ning Wang, Fengli Huang, Xingzhi Han, Zhihao Liu, Xiao Shi, Qun Zhang, Jing Hu, Xiaoping Qian. (2025) Evaluation of the anti-tumor effect of gambogic acid loaded macrophage membranes nanoparticles combined with radiotherapy and anti-PD-1mAb in the colorectal cancer with liver metastasis model. Biomaterials Advances, [PMID:40829297] [10.1016/j.bioadv.2025.214463] |
| 15. Xiongqin Wang, Kunhui Sun, Junlin Dong, Yanli Ge, Haifan Liu, Xingyue Jin, Xiao Pei, Ping Wang, Jianbing Jiang, Tiejie Wang, Xuelei Hu, Shuguang Yuan, Bing Wang, Xie-an Yu. (2025) Carrier-free nanoparticles based on natural products trigger dual "synergy and attenuation" for enhanced phototherapy of liver cancer. Materials Today Bio, [PMID:40984881] [10.1016/j.mtbio.2025.102278] |
| 16. Xinxin Chen, Jiang Sun, Tingxian Ye, Fanzhu Li. (2025) Neutrophil-Camouflaged Stealth Liposomes for Photothermal-Induced Tumor Immunotherapy Through Intratumoral Bacterial Activation. Pharmaceutics, 17 (5): (614). [PMID:40430905] [10.3390/pharmaceutics17050614] |
| 17. Qiao Yang, Liu Menghui, Zhang Yiqun, Ni Fan, Yu Liangchen, Chen Zhao, Dai Xingliang, Wang Xianwen. (2025) Gambogic acid-iron nanozymes as effective carriers for enhanced chemotherapy by inducing excessive autophagy and oxidative stress. JOURNAL OF NANOBIOTECHNOLOGY, 23 (1): (1-23). [PMID:40495160] [10.1186/s12951-025-03519-3] |
| 18. Yanbin Chen, Xiaodong Xu, Xinye Hu. (2025) Design and fabrication of polymer-coated vincristine-loaded core − shell iron nanoparticle system with mitochondrial-targeted ultrasound improved colorectal cancer therapy. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, [PMID:40489545] [10.1080/09205063.2025.2501095] |
| 19. Jiajian Wang, Lanqing Zhang, Runfang Li, Rui Yang, Fan Yang, Fei Yu, Jihong Zhang. (2025) Gambogic acid restores wild-type-like p53 functions to induce ferroptosis in mutant p53 cancer cells. BIOCHEMICAL PHARMACOLOGY, [PMID:41213406] [10.1016/j.bcp.2025.117533] |
| 20. Menghui Liu, Yang Qiao, Sheng Cheng, Ziqing Su, Ziyi Li, Peng Gao, Xianwen Wang, Qiang Cai, Xingliang Dai. (2025) 3D bioprinted microneedle patches loaded with gambogic acid-iron-doxorubicin nanozymes for postoperative glioma in situ therapy via ferroptosis synergistic chemosensitization. JOURNAL OF NANOBIOTECHNOLOGY, [PMID:41272423] [10.1186/s12951-025-03790-4] |
| 21. Liuqi Sang, Qun Zhang, Zixin Liang, Xinyi Xu, Xueying Bai, Ning Wang, Xingzhi Han, Li Li, Jing Hu, Xiaoping Qian. (2025) Application of radiotherapy-preexcited gambogic acid dual targeting nanoparticles in colorectal cancer. RSC Advances, 15 (55): (47506-47519). [PMID:41356714] [10.1039/D5RA02815A] |
| 22. Yu Chao, Yao Liyuan, Du Xinyu, Yu Jianjun, Wang Yanjin, Hou Xiying, Shen Fengchen, Liu Na, Zhuang Shougang. (2025) Genetic depletion or pharmacological degradation of EZH2 attenuates renal fibrosis via suppressing Notch signaling. Clinical Epigenetics, 18 (1): (12). [PMID:41351132] [10.1186/s13148-025-02013-9] |
| 23. Xin Wang, Chenfang Ban, Xuejing Li, Jin Wang, Bangping Cao, Wenjing Wu, Zhanwei Zhang, Jiansheng Su. (2026) Bioinspired Lipid Droplets Nanoplatform for Periodontitis Therapy: Integrated Antibacterial, Mitochondrial Repair, and Immunomodulatory Functions. Materials Today Bio, [PMID:41624519] [10.1016/j.mtbio.2026.102808] |
| 24. Ruizhe Xu, Xuejing Li, Xiaomin Su, Xifeng Qin, Ying He, Siyu Wang, Yue Liu, Jiayi Wu, Ting Wang, Mingyang Liu, Boshu Ouyang, Jia Li, Wuli Yang, Bo Zhang, Zhiqing Pang. (2026) Biomimetic liposomes synergize with high-intensity focused ultrasound to induce ferroptosis in tumors. Acta Pharmaceutica Sinica B, [PMID:] [10.1016/j.apsb.2026.02.024] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →